Federal Rescheduling of Cannabis: An Expert Panel
Join our one-hour webinar to discuss possible changes on the horizon in federal drug policy.
In late 2025, President Trump signed an Executive Order to expedite the rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act.
If finalized, the reclassification would mark a significant policy shift with concrete legal, economic, and research implications. What does this mean for recreational/medical use, state and federal drug law, and cannabis research?
Our panel of experts bring multidisciplinary perspectives to this complicated issue.
Panelists
MASON MARKS
Professor, Florida State University College of Law; Senior Fellow, POPLAR, Petrie-Flom Center, Harvard Law School
DR. PETER GRINSPOON
Primary care physician, cannabis and addiction specialist, Massachusetts General Hospital; Instructor, Harvard Medical School
IFETAYO HARVEY
Executive Director, People of Color Psychedelic Collective; POPLAR Affiliated Researcher, Petrie-Flom Center, Harvard Law School
HIRSH JAIN
CEO, Ananda Strategy; Vice Chair, Cannabis Chamber of Commerce, HLS ’12
ROBERT MIKOS
Professor, Vanderbilt Law School; POPLAR Affiliated Researcher, Petrie-Flom Center, Harvard Law School
This event is organized by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, with support from the Oswald DeN. Cammann Fund at Harvard University and the Gracias Family Foundation.